Bank of America
HUMA icon

Bank of America’s Humacyte HUMA Stock Holding History

Bank of America’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$451K Buy
578,592
+182,479
+46% +$169K ﹤0.01% 5015
2026
Q1 		$240K Sell
396,113
-56,095
-12% -$58.3K ﹤0.01% 5264
2025
Q4 		$434K Sell
452,208
-28,801
-6% -$40.8K ﹤0.01% 4981
2025
Q3 		$837K Sell
481,009
-22,310
-4% -$43.7K ﹤0.01% 5446
2025
Q2 		$1.05M Sell
503,319
-397,486
-44% -$764K ﹤0.01% 5271
2025
Q1 		$1.54M Buy
900,805
+303,486
+51% +$1.14M ﹤0.01% 4910
2024
Q4 		$3.02M Buy
597,319
+367,720
+160% +$1.82M ﹤0.01% 4078
2024
Q3 		$1.25M Buy
229,599
+8,451
+4% +$55.7K ﹤0.01% 4906
2024
Q2 		$1.06M Buy
221,148
+181,781
+462% +$946K ﹤0.01% 4871
2024
Q1 		$122K Sell
39,367
-40,614
-51% -$137K ﹤0.01% 6146
2023
Q4 		$227K Buy
79,981
+26,407
+49% +$67.8K ﹤0.01% 6005
2023
Q3 		$157K Buy
53,574
+41,467
+343% +$137K ﹤0.01% 6031
2023
Q2 		$34.6K Sell
12,107
-23,212
-66% -$83.7K ﹤0.01% 6570
2023
Q1 		$109K Sell
35,319
-78,035
-69% -$222K ﹤0.01% 6223
2022
Q4 		$239K Buy
113,354
+67,927
+150% +$206K ﹤0.01% 5814
2022
Q3 		$148K Sell
45,427
-28,239
-38% -$108K ﹤0.01% 6146
2022
Q2 		$236K Buy
73,666
+49,762
+208% +$277K ﹤0.01% 5966
2022
Q1 		$169K Buy
23,904
+17,017
+247% +$99.1K ﹤0.01% 6567
2021
Q4 		$51K Buy
6,887
+3,385
+97% +$33.5K ﹤0.01% 7211
2021
Q3 		$40K Buy
3,502
+3,002
+600% +$34.3K ﹤0.01% 7146
2021
Q2 		$5K Buy
+500
New +$5.15K ﹤0.01% 7426

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America's HUMA Position: Q2 2026 in Review

Bank of America increased its Humacyte (HUMA) stake by 46% in Q2 2026, buying an estimated $169K and bringing the position to 578,592 shares worth $451K. The position accounts for ﹤0.01% of the portfolio, ranked #5015.

Bank of America first reported a position in HUMA in Q2 2021 and has held it in 21 quarters since. The position peaked at $3.02M in Q4 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Bank of America held 578,592 shares of Humacyte worth $451K as of Q2 2026.
  • Bank of America bought 182,479 Humacyte shares in Q2 2026, an estimated $169K.
  • Humacyte made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5015 holding.
  • Bank of America first reported a position in Humacyte in Q2 2021 and has held it in 21 quarters since.
  • Bank of America's Humacyte position peaked at $3.02M in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.